{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T05:27:17Z","timestamp":1732771637253,"version":"3.29.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,27]]},"DOI":"10.7759\/cureus.74576","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T12:35:43Z","timestamp":1732710943000},"source":"Crossref","is-referenced-by-count":0,"title":["Achievement of Clinical Remission in Life-Threatening Rosai-Dorfman Disease With Cladribine"],"prefix":"10.7759","author":[{"given":"Lex P","family":"Leonhardt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yamagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Harcha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity","volume":"87","author":"Rosai J","year":"1969","unstructured":"Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity. Arch Pathol. 1969, 87:63-70.","journal-title":"Arch Pathol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-839753","article-title":"Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease","volume":"131","author":"Abla O","year":"2018","unstructured":"Abla O, Jacobsen E, Picarsic J, et al.. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood. 2018, 131:2877-90. 10.1182\/blood-2018-03-839753","journal-title":"Blood"},{"key":"ref3","article-title":"Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): Review of the entity","volume":"7","author":"Foucar E","year":"1990","unstructured":"Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): Review of the entity. Semin Diagn Pathol. 1990, 7:19-73.","journal-title":"Semin Diagn Pathol"},{"key":"ref4","article-title":"Pulmonary manifestations revealing Rosai-Dorfman disease","volume":"32","author":"Goupil de Bouill\u00e9 J","year":"2015","unstructured":"Goupil de Bouill\u00e9 J, de Muret A, Diot E, Dumont P, Plantier L, Diot P, Marchand-Adam S. Pulmonary manifestations revealing Rosai-Dorfman disease. Sarcoidosis Vasc Diffuse Lung Dis. 2015, 32:275-7.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.5582\/irdr.2015.01047","article-title":"Rosai-Dorfman disease and the heart","volume":"5","author":"O'Gallagher K","year":"2016","unstructured":"O'Gallagher K, Dancy L, Sinha A, Sado D. Rosai-Dorfman disease and the heart. Intractable Rare Dis Res. 2016, 5:1-5. 10.5582\/irdr.2015.01047","journal-title":"Intractable Rare Dis Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.08.1114","article-title":"Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): Imaging manifestations in the head and neck","volume":"191","author":"La Barge DV 3rd","year":"2008","unstructured":"La Barge DV 3rd, Salzman KL, Harnsberger HR, Ginsberg LE, Hamilton BE, Wiggins RH 3rd, Hudgins PA. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): Imaging manifestations in the head and neck. AJR Am J Roentgenol. 2008, 191:W299-306. 10.2214\/AJR.08.1114","journal-title":"AJR Am J Roentgenol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00297","article-title":"A single case of rosai-dorfman disease marked by pathologic fractures, kidney failure, and liver cirrhosis treated with single-agent cladribine","volume":"4","author":"Sasaki K","year":"2014","unstructured":"Sasaki K, Pemmaraju N, Westin JR, et al.. A single case of rosai-dorfman disease marked by pathologic fractures, kidney failure, and liver cirrhosis treated with single-agent cladribine. Front Oncol. 2014, 4:297. 10.3389\/fonc.2014.00297","journal-title":"Front Oncol"},{"key":"ref8","article-title":"Dramatic clinical efficacy of cladribine in Rosai-Dorfman disease and evolution of the cytokine profile: Towards a new therapeutic approach","volume":"91","author":"Aouba A","year":"2006","unstructured":"Aouba A, Terrier B, Vasiliu V, Candon S, Brousse N, Varet B, Hermine O. Dramatic clinical efficacy of cladribine in Rosai-Dorfman disease and evolution of the cytokine profile: Towards a new therapeutic approach. Haematologica. 2006, 91:ECR52.","journal-title":"Haematologica"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.06.013","article-title":"Rosai-Dorfman disease: The MD Anderson Cancer Center experience","volume":"11","author":"Sathyanarayanan V","year":"2019","unstructured":"Sathyanarayanan V, Issa A, Pinto R, Fayad LE, Loghavi S, Hagemeister F, Westin JR. Rosai-Dorfman disease: The MD Anderson Cancer Center experience. Clin Lymphoma Myeloma Leuk. 2019, 11:709-714. 10.1016\/j.clml.2019.06.013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.219626","article-title":"Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease","volume":"105","author":"Goyal G","year":"2020","unstructured":"Goyal G, Ravindran A, Young JR, et al.. Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. Haematologica. 2020, 105:348-57. 10.3324\/haematol.2019.219626","journal-title":"Haematologica"},{"key":"ref11","unstructured":"Cladribine. (2024). Accessed. September 01, 2024: https:\/\/medlineplus.gov\/druginfo\/meds\/a619038.html#:~:text=Cladribine%20is%20used%20to%20treat,relapsing%2Dremitting%...."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.55","article-title":"Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease","volume":"30","author":"Garces S","year":"2017","unstructured":"Garces S, Medeiros LJ, Patel KP, et al.. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease. Mod Pathol. 2017, 30:1367-77. 10.1038\/modpathol.2017.55","journal-title":"Mod Pathol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/298589-achievement-of-clinical-remission-in-life-threatening-rosai-dorfman-disease-with-cladribine","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T12:35:45Z","timestamp":1732710945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/298589-achievement-of-clinical-remission-in-life-threatening-rosai-dorfman-disease-with-cladribine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.74576","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,27]]}}}